HEC PHARM
GenericsHEC PHARM is a generic drug manufacturer focused on Infectious Disease, Gastroenterology, Cardiovascular.
HEC PHARM's Key Drugs
HEC PHARM's core commercial portfolio centers on PRASUGREL, spanning Infectious Disease and Gastroenterology — its most strategically important drugs approved in the last 15 years.
HEC PHARM's Recent FDA Approvals
New NDA/BLA approvals for HEC PHARM over the last two years — novel drugs only, excluding generics and label supplements.
HEC PHARM's Therapeutic Areas
HEC PHARM's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Gastroenterology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HEC PHARM's Top Competitors
HEC PHARM's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HEC PHARM Pipeline Snapshot
Active clinical trials for HEC PHARM across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PRASUGREL leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2011-10-07
- Latest
- 2024-09-20
- Applications
- 7